Clinical And Therapeutic Studies Of Human Filariasis

为了更好地了解丝虫感染（盘尾丝虫病、洛伊斯病、淋巴丝虫病）的发病机制，对这些和其他相关非丝虫（类圆线虫病、疟疾）感染患者的临床评估进行了详细研究。此外，治疗后的炎症反应及其诱导的潜在机制已被详细说明。特别是，已经研究了嗜酸性粒细胞诱导和细胞运输到治疗后炎症部位的控制。Wolbachia内共生体作为治疗靶点和作为炎症诱导剂的重要性也已详细说明。 在2003财政年度，我们证明了伊维菌素/阿苯达唑治疗马里淋巴丝虫病后的不良反应相对较少，并表明与持久性曼森氏菌合并感染对治疗后反应的改变很小。

To understand better the pathogenesis of filarial infections (onchocerciasis, loiaisis, lymphatic filarasis) clinical assessments of patients with these and other related non-filarial (strongyloides, malaria) infections have been studied in detail. Moreover, the post-treatment inflammatory responses and the underlying mechanisms in their induction have been detailed. In particular, the control of eosinophil induction and cell trafficking to sites of post-treatment inflammation has been studied. The importance of the Wolbachia endosymbiont both as a therapeutic target and as a inducer of inflammation has been detailed as well. In FY 2003, we demonstrated the relative paucity of adverse reactions seen following ivermectin/albendazole treatment of lymphatic filariasis in Mali and have shown that co-infection with Mansonella perstans does little to alter the post-treatment reactions.